Aldeyra Therapeutics, Inc.
ALDXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Aldeyra Therapeutics, Inc. focuses on Biotechnology services and products. Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. At a $39.2M market cap, Aldeyra Therapeutics, Inc. ranks as a micro-cap company within healthcare. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Market Cap
$39.2M
Beta
1.20
P/E (TTM)
—
P/E (Fwd)
-2.36
EPS (TTM)
$-0.38
EPS (Fwd)
$-0.28
ROE
-49.5%
ROA
-22.7%
Cash
$45.1M
Total Debt
$143,447
Free CF
-$15.6M
52W Change
-87.6%
Annual Financials
Cash vs Debt
Where ALDX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ALDX finished 58.13% below its 150-day moving average ($1.60) and 72.54% below its 200-day moving average ($2.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALDX overbought or oversold?
At the October 20, 2026 close, ALDX's RSI(14) was 12.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $45.1M in cash comfortably exceeding the $143K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$15.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -49.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, ALDX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aldeyra Therapeutics, Inc.'s trajectory.